PUBLICATIONS AGNES JAGER: 1. Milne RL, Herranz J, Michailidou K, Jager A,. Malats N, Easton DF. A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet. 2014;23:1934-46 2. M. Kriege M, Hollestelle A, Jager A, Huijts PEA, Berns EM, Sieuwerts AM, Meijer-van Gelder ME, Collée JM, Devilee P, Hooning MJ, Martens JWM, Seynaeve S. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer. 2014 Jun 10. [Epub ahead of print] 3. Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens J, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter J, Vreeswijk M, Jager A, van Gent DC. Ex vivo assessment of Homologous Recombination reveals different modes of BRCA gene silencing in p rimary breast tumors Clinical Cancer research 2014; Epub ahead of print 4. Heemskerk BAM, Menke-Pluijmers MBE, Jager A, Tilanus-Linthorst MMA, Koppert LB, Obdeijn IMA, van Deurzen CHM, Collee JM, Seynaeve C, Hooning MJ. Substantial breast cancer risk-reduction and improved survival after bilateral mastectomy in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 2013;24:2029-35 5. Drooger JC, van der Padt A, Sleijfer S, Jager A. Denosumab in breast cancer treatment. Eur J Pharmacol. 2013;717:12-9 6. Georgieva RD, Obdeijn IM, Jager A, Hooning MJ, Tilanus-Linthorst MM, van Deurzen CH. Breast fineneedle aspiration cytology performance in the high-risk screening population: A study of BRCA1/BRCA2 mutation carriers. Cancer Cytopathol. 2013;121:561-7 7. Binkhorst L, Mathijssen RH, van Herk-Sukel MP, Bannink M, Jager A, Wiemer EA, van Gelder T. Unjustified prescribing of CYP2D6 inhibiting SSRI's in women treated with tamoxifen. Breast Cancer Res Treat. 2013 Jun;139(3):923-9. 8. Michailidou K, Hall P, Gonzalez-Niera A,. Jager A,. Benitez J, Easton DF. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013 45:353-61. 9. Bojesen SE, Pooley KA, Johnatty SE, Jager A, Chenevix-Trench G, Dunning AM. Multiple independent TERT variants are associated with telomere length and breast cancer risk. Nat Genet. 2013 45:371-84 10. Rakha EA, Tan PH, Shaaban A, Tse GM, Esteller FC, van Deurzen CH, Purnell D, Stotter A, Chan T, Yamaguchi R, Dodwell D, Jager A, Soler MT, Juneinah E, Plaza ML, Hodi Z, McCulloch T, Lee AH, Ellis IO. Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast. 2013;22:13-8. 1
11. Vencken PMLH, Kriege M, Hooning M, Menke-Pluymers MB, Heemskerk A, van Doorn H, Collée, M, Jager A, van Montfort C, Burger CW, Seynaeve CM. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/2 mutation carriers; implications for counselling. Cancer 2013;119:955-62 12. Ding YC, McGuffog L, Healey S,, Jager A,., Antoniou AC, Neuhausen SL; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21:1362-70. 13. Warren H, Dudbridge F, Fletcher O, Jager A,.Peto J, Dos-Santos-Silva I. 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2012;21:1783-1791. 14. Fasching PA, Pharoah PD, Cox A,.Jager A,, Easton DF, Schmidt MK. The role of genetic breast cancer susceptibility loci as prognostic factors. The role of genetic breast cancer susceptibility loci as prognostic factors. Hum Mol Genet. 2012;21:3926-39 15. Vos de FYFL, van Laarhoven HMW, Laven JSE. Themmen APN, Beex LVAM, Sweep CGJ, Seynaeve CM, Jager A. Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. Crit Rev Oncol Hematol 2012;84:252-60. 16. de Raaf PJ, Sleijfer S, Lamers C, Jager A, Gratama JW, van der Rijt CCD. Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study. Cancer. 2012;118:6005-11 17. Oldenmenger WH, Lieverse PJ, Janssen PJ, Taal W, van der Rijt CC, Jager A. Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids. Support Care Cancer. 2012;20:1639-47 18. Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve CM, van Schaik RH, Verweij J, Mathijssen RH. Effects of CYP induction by Rifampicin on Tamoxifen Exposure. Clin Pharmacol Ther. 2012;92:62-67 19. Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 2012;118:899-907. 20. Ramus SJ, Kartsonaki C, Gayther SA,. Jager A,..., Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2011;103:105-116. 21. Manders P, Pijpe A, Hooning MJ, Jager A,.van Leeuwen FE, Rookus MA. Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2011;126:193-202. 2
22. Osorio A, Milne RL, Alonso R,... Jager A,..., Radice P, Benítez J; CIMBA. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. Br J Cancer. 2011;104:1356-1361. 23. Yang XR, Chang-Claude J, Goode EL, Jager A,., Sherman ME, Garcia-Closas M. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst. 2011;103:250-263. 24. van Deurzen CH, Lee AH, Gill MS, Menke-Pluijmers MB, Jager A, Ellis IO, Rakha EA. Metaplastic breast carcinoma: tumor histogenesis or dedifferentiation? J Pathol. 2011;224:434-437. 25. Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, Berns EM, Jager A, Collée M, Burger CW, Seynaeve C. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first line chemotherapy compared with sporadic ovarian cancer patients. Annals of Oncology 2011;22:1346-1352 26. Antoniou AC, Beesley J, McGuffog L,. Jager A,.., Chenevix-Trench G, Easton DF; CIMBA. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70:9742-9754. 27. Antoniou AC, Wang X, Fredericksen ZS, Jager A,..., Easton DF, Couch FJ. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptornegative breast cancer in the general population. Nat Genet. 2010;42:885-892 28. Broeks A, Schmidt MK, Sherman ME, Jager A,., Pharoah PD, Garcia-Closas M. for the Breast Cancer Association Consortium. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: Findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20:3289-3303. 29. Gaudet MM, Kirchhoff T, Green T, Jager A,., Spurdle AB, Chenevix-Trench G. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet. 2010 28;6:e1001183. 30. Johnatty SE, Couch FJ, Fredericksen Z,. Jager A,., Easton DF, Chenevix-Trench G; Breast Cancer Association Consortium and Consortium of Investigators of Modifiers of BRCA1/2. No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat. 2009;117:371-379 31. Jager A, Verweij J, Sleijfer S. Adjuvant chemotherapy in older breast cancer patients. Nature reviews clinical oncology. 2009;6:563-565 32. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MBE, Bartels CCM, Tilanus- Linthorst MMA, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hooning MJ, Brekelmans CTM, Klijn JGM. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology. 2009;27:3764-3771 3
33. Jager A, Sleijfer S, van der Rijt CCD. Pathogenesis of cancer related fatigue: Could increased proinflammatory cytokine activity be the common denominator? European Journal of Cancer 2008;44:175-181 34. Juffermans NP, Jager A, Kersten MJ, van Oers MH, Hommes DW. Epstein-Barr-virus-gerelateerde lymfomen bij patiënten met inflammatoire darmziekte. Nederlands Tijdschrift voor Geneeskunde 2005;149:1859-1863 35. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ. Verhoogde glucoseconcentraties in nuchtere toestand en na glucosebealsting: risicofactoren van het otstaan van diabetes mellitus type 2; uitresultaten van de Hoorn-studie. Nederlands Tijdschrift voor geneeskunde 2003;147:1414-1418 36. Patel JN, Jager A, Schalkwijk C, Corder R, Douthwaite JA, Yudkin JS, Coppack SW, Stehouwer CDA. Effects of tumor necrosis factor- in the human forearm: blood flow and endothelin-1 release. Clinical Science 2002;103:409-415 37. Spijkerman AW, Dekker JM, Nijpels G, Jager A, Kostense PJ, van Hinsbergh VWM, Bouter LM, Heine RJ, Stehouwer CDA. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: The Hoorn Study. European Journal of Clinical Investigation 2002;32:924-930 38. Jager A, van Hinsbergh VWM, Kostense PJ, Nijpels G, Emeis JJ, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. C-reactive protein and soluble vascular cellular adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arteriosclerosis, Thrombosis and Vascular Biology 2002; 22:593-598 39. Becker A, van Hinsbergh VWM, Jager A, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Why is a high plasma level of soluble intercellular adhesion molecule-1 related to cardiovascular mortality in diabetic and nondiabetic subjects? European Journal of Clinical Investigation 2002;32:1-8 40. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001;285:2109-2113. 41. Jager A, van Hinsbergh VWM, Nijpels G, Emeis JJ, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. Prognostic implications of retinopathy and/or endothelial dysfunction in non-insulin-dependent diabetic subjects with microalbuminuria. Nephrology, Dialysis and Transplantation, 2001 16:529-536 42. Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. Serum homocysteine levels are associated with the development of (micro)albuminuria: Follow-up of the Hoorn Study. Arteriosclerosis, Thrombosis and Vascular Biology 2001;21:74-84 4
43. Smulders YM, Jager A, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Impaired cardiovascular autonomic function is associated with (micro-)albuminuria in elderly Caucasian subjects with impaired glucose tolerance or NIDDM: The Hoorn Study. Diabetes Care 2000;23:1369-1374 44. Becker A, van Hinsbergh VWM, Kostense PJ, Jager A, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and nondiabetic subjects; the Hoorn Study. European Journal of Clinical Investigation 2000;30:763-770 45. Jager A, van Hinsbergh VWM, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. Increased levels of soluble vascular cell adhesion molecule 1 (svcam-1) are associated with risk of cardiovascular mortality in non-insulin-dependent diabetes mellitus: The Hoorn Study. Diabetes 2000;49:485-491 46. Jager A, Stehouwer CDA. Early detection of diabetic and non-diabetic subjects with increased cardiovascular risk: new risk indicators. Heart and Metabolism 1999;5:4-14 47. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers HGT, Schlingermann RO, Tarnow L, Parving H-H, Stehouwer CDA, van Hinsbergh VWM. Amadori-albumin in type I diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy and localization in retinal capillaries. Diabetes 1999;48:2446-2453 48. Jager A, van Hinsbergh VWM, Kostense PJ, Nijpels G, Yudkin JS, Emeis JJ, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. Von Willebrand factor, C-reactive protein and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn Study. Arteriosclerosis, Thrombosis and Vascular Biology, 1999 ;19:3071-3078 49. Jager A, Kostense PJ, Ruhe HG, Nijpels G, Dekker JM, Bouter LM, Stehouwer CDA. Microalbuminuria and peripheral arterial disease are independent predictors of all-cause and cardiovascular mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study. Arteriosclerosis, Thrombosis and Vascular Biology 1999;19:617-624 50. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jacobs C, Bouter LM, Donker AJM, Stehouwer CDA. Serum homocysteine level and protein intake are related to risk of (micro) albuminuria: a population based study. Kidney International 1998;54:203-209 51. Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Microalbuminuria is strongly associated with NIDDM and hypertension but not with the insulin resistance syndrome: The Hoorn Study. Diabetologia 1998;41:694-700 52. Stehouwer CDA, Jager A, Donker AJM. Capita Selecta: Microalbuminurie bij essentiële hypertensie: van betekenis voor het aanwijzen van patiënten met een hoog risico voor complicaties. Nederlands Tijdschrift voor Geneeskunde 1997;34:1649-1653 5
53. Dolman KM, Jager A, Sonnenberg A, Kr. von dem Borne AEG, Goldschmeding R. Proteolysis of classic anti neutrophil cytoplasmic autoantibodies (C-ANCA) by neutrophil proteinase 3. Clinical Experimental Immunology 1995;101:8-12 6